We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Featured News

 

Latest News

RNTECH and DNAVision Announce Co-Marketing Agreement
RNTECH and DNAVision Announce Co-Marketing Agreement
News   Feb 01, 2006

This Agreement will provide solutions for biomarker and target discovery in oncology.

READ MORE

Researchers Give Link Between RNAi and Telomere Length
Researchers Give Link Between RNAi and Telomere Length
News   Feb 01, 2006

Researchers discover two known components of the Drosophila RNAi machinery regulate the transposition of telomeric retrotransposons.

READ MORE

Illumina Appoints Matthew Posard to Lead Worldwide Marketing
Illumina Appoints Matthew Posard to Lead Worldwide Marketing
News   Feb 01, 2006

Matthew L. Posard has been appointed as Vice President of Marketing.

READ MORE

A Real Time Look at Interactions Between RNA and Proteins
A Real Time Look at Interactions Between RNA and Proteins
News   Feb 01, 2006

Researchers study how manipulation of cellular physiology, such as administering a drug, changes RNA-binding protein and RNA interactions.

READ MORE

RxP and BioTrove Announce Collaboration
RxP and BioTrove Announce Collaboration
News   Jan 31, 2006

The Companies will provide primate-human transcription and SNP assays for toxicology.

READ MORE

Medistem Reports Method of Immunomodulation
Medistem Reports Method of Immunomodulation
News   Jan 31, 2006

Medistem has developed the method of immune response modification utilizing a genetic reprogramming technology involving RNAi.

READ MORE

CytRx Accelerates RNAi Therapeutics Programs
CytRx Accelerates RNAi Therapeutics Programs
News   Jan 31, 2006

CytRx plans to form a new subsidiary to accelerate the development and commercialization RNAi based drugs.

READ MORE

Clinical Data Initiates Phase III Trial for Antidepressant 'Vilazodone'
Clinical Data Initiates Phase III Trial for Antidepressant 'Vilazodone'
News   Jan 31, 2006

The outcome of this trial would serve as one of two pivotal trials required for a new drug application.

READ MORE

Stratagene Posts $21-Million Bond to Secure Damages Awarded to Third Wave
Stratagene Posts $21-Million Bond to Secure Damages Awarded to Third Wave
News   Jan 30, 2006

The jury has found Stratagene liable for willful patent infringement.

READ MORE

NCBI Adopts Standard for Accepting 454's Sequencing Data
NCBI Adopts Standard for Accepting 454's Sequencing Data
News   Jan 30, 2006

First sequence trace format adopted by NCBI since Sanger method.

READ MORE